Evidence map›Paper›PMID 18042302›Full record

ArticleBMC health services research2007

The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study.

Scott R Berry, Stacey Hubay, Hagit Soibelman, Douglas K Martin

Abstract read
In one paragraph

Article in BMC health services research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Navigating Ethical Practices in the Era of High Cost Hematology.Current hematologic malignancy reports · 2020
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Access to cancer drugs in Canada: looking beyond coverage decisions.Healthcare policy = Politiques de sante · 2011
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Scott R BerryDivision of Medical Oncology/Hematology, Sunnybrook Health Sciences Centre, Department of Medicine, University of Toronto, Toronto, Canada. scott.berry@sunnybrook.ca
Stacey Hubay
Hagit Soibelman
Douglas K Martin

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHealth care policies, including drug-funding policies, influence physician practice. Funding policies are especially important in the area of cancer care since cancer is a leading cause of death that is responsible for a significant level of health care expenditures. Recognizing the rising cost of cancer therapies, Cancer Care Ontario (CCO) established a funding process to provide access to new, effective agents through a "New Drug Funding Program" (NDFP). The purpose of this study is to describe oncologists' perceptions of the impact of NDFP priority setting decisions on their practice.

methodsThis is a qualitative study involving semi-structured, in-depth interviews with 46 medical oncologists in Ontario. Oncologists were asked to describe the impact of CCO's NDFP drug funding decisions on their practice. Analysis of interview transcripts commenced with data collection.

resultsOur key finding is that many of the medical oncologists who participated in this study did not accept limits when policy decisions limit access to cancer drugs they feel would benefit their patients. Moreover, overcoming those limits had a significant impact on oncologists' practice in terms of how they spend their time and energy and their relationship with patients.

conclusionWhen priority setting decisions limit access to cancer medications, many oncologists' efforts to overcome those limits have a significant impact on their practice. Policy makers need to seriously consider the implications of their decisions on physicians, who may go to considerable effort to circumvent their policies in the name of patient advocacy.

Indexed as

Attitude of Health PersonnelHealth PolicyPhysician-Patient RelationsProfessional AutonomyAntineoplastic AgentsDecision MakingDrug ApprovalFemaleHealth PrioritiesHealth Services AccessibilityHumansInterviews as TopicMaleMedical OncologyNeoplasmsOntarioAntineoplastic Agents

Identifiers

PMID18042302
PMCPMC2148046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.